(Q38743961)

6 September 2017

title

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. (English)

1 reference

6 September 2017

1 reference

1 reference

18

Jose Baselga

1 reference

6 September 2017

Christelle Levy

13

0 references

Evandro de Azambuja

object named as

Evandro de Azambuja

3

0 references

Giuseppe Viale

6

object named as

Giuseppe Viale

1 reference

6 September 2017

Bruno Coudert

0 references

Luís Fernández-Morales

0 references

Denise A Yardley

14

object named as

Denise A Yardley

1 reference

6 September 2017

2

Marion Procter

1 reference

6 September 2017

Gunter von Minckwitz

1

1 reference

6 September 2017

Dimitrios Zardavas

4

1 reference

6 September 2017

Mark Benyunes

5

1 reference

6 September 2017

Thomas Suter

7

1 reference

6 September 2017

Amal Arahmani

8

1 reference

6 September 2017

Nathalie Rouchet

9

1 reference

6 September 2017

Emma Clark

10

1 reference

6 September 2017

Adam Knott

11

1 reference

6 September 2017

Istvan Lang

12

1 reference

6 September 2017

Jose Bines

15

1 reference

6 September 2017

Richard D Gelber

16

1 reference

6 September 2017

Martine Piccart

17

1 reference

6 September 2017

APHINITY Steering Committee and Investigators

19

1 reference

6 September 2017

language of work or name

English

0 references

publication date

5 June 2017

1 reference

The New England Journal of Medicine

6 September 2017

published in

1 reference

6 September 2017

volume

377

1 reference

6 September 2017

issue

2

1 reference

6 September 2017

page(s)

122-131

1 reference

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

6 September 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538020

Translating neoadjuvant therapy into survival benefits: one size does not fit all.

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538020

Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538020

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538020

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

4 November 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538020

4 November 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538020

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study

3 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538020

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538020

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538020

Adjuvant trastuzumab in HER2-positive breast cancer

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538020

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538020

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538020

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538020

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538020

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

4 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28581356

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1703643

1 reference

6 September 2017

0 references

1 reference